A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients
M6229 was deemed safe to use in critically ill sepsis patients. Our results suggest intravascular neutralization of histones by M6229. Future clinical studies need to confirm our findings and the efficacy of M6229.
Authors
- Niels van Mourik (ORCID: https://orcid.org/0000-0003-3826-4135)
- Femke de Vries (ORCID: https://orcid.org/0000-0002-4281-0779)
- Marleen A. Slim (ORCID: https://orcid.org/0000-0002-6281-040X)
- Rombout B. E. van Amstel (ORCID: https://orcid.org/0000-0001-9296-8518)
- Chris Reutelingsperger (ORCID: https://orcid.org/0000-0002-2334-9403)
- Peter F. Ekhart (ORCID: https://orcid.org/0000-0002-0164-2633)
- Gerry A. F. Nicolaes (ORCID: https://orcid.org/0000-0002-2482-0412)
- Tom van der Poll (ORCID: https://orcid.org/0000-0002-9199-5079)
- Lonneke A. van Vught (ORCID: https://orcid.org/0000-0002-0152-3044)
- Marcella S. Müller (ORCID: https://orcid.org/0000-0003-3884-1908)
- Joram Huckriede (ORCID: https://orcid.org/0009-0004-7577-0154)
- Alexander P. J. Vlaar (ORCID: https://orcid.org/0000-0002-3453-7186)
- Sjef J. de Kimpe
- R. Crabbé
- Simone J. M. van Leeuwen
Institutions
- DSM (Netherlands) (NL)
- Maastricht University (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Intensive Care Medicine Experimental
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1186/s40635-025-00790-4
- Primary Topic
- Sepsis Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00